Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 16th September 2024 (Draft)

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 10th June 2024 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Abacavir 600mg/Lamivudine 300mg Tablets**
- **Biktarvy® (Bictegravir 50mg / Emtricitabine 200mg /Tenofovir alafenamide 25mg) Tablet**
- **Cabotegravir 30mg Tablets (Vocabria®)**
- **Descovy® (Tenofovir alafenamide 25mg and Emtricitabine 200mg) Tablet**
- **Descovy® (Tenofovir alafenamide 10mg and Emtricitabine 200mg) Tablet**
- **Dovato® (Dolutegravir 50mg / Lamivuidine 300mg) Tablet**
- **Fostemsavir 600mg Prolonged Release Tablets**
- **Genvoya® (Emtricitabine 200mg / Tenofovir alafenamide 10mg / Elvitegravir 150mg / Cobicistat 150mg) Tablet**
- **Juluca® (Dolutegravir 50mg / Rilpivirine 25mg) Tablet**
- **Odefsey® (Emtricitabine 200mg / Rilpivirine 25mg / Tenofovir alafenamide 25mg) Tablet**

Requested by: HIV/GUM
Indication: Management of HIV
Proposal: Add to the formulary in line with their licensed indication in line with NHS Commissioning Guidance on use of ARVs.
Approved previously by the Clinical Directorate of HIV, Sexual Health and Gender Health Medicines Sub Group.
For noting.
Outcome: Approved for addition to the formulary

- Abrysvo powder and solvent for solution for injection (Respiratory Syncytial Virus Vaccine (bivalent, recombinant))

Requested by: Maternity
Indication: Respiratory Syncytial Virus vaccination of maternity patients Proposal: Add to the formulary to support vaccination of maternity patients in line with the new National RSV Vaccine Schedule:
All women who are at least 28 weeks pregnant (the eligible cohort) on 1 September 2024, should be offered a single dose of the RSV vaccine, through commissioned services. After that, pregnant women will become eligible as they reach 28 weeks gestation and remain eligible up to birth.
Cost: FOC
Likely to treat: All maternity patients from 28 weeks gestation at both hospital sites
Outcome: Approved for addition to the formulary

Ex-Panel

- **Anthelios® SPF50+ Sunscreen**

Requested by: Dermatology Indication: Sunscreen SPF 50+
Proposal: Add to the formulary as the first line 50+ sunscreen for skin protection against ultraviolet radiation and/or visible light in abnormal cutaneous photosensitivity causing severe cutaneous reactions in genetic disorder.
Will replace:

- Anthelios XL® SPF 50+ Melt-in Cream
- Sunsense Ultra® SPF 50+ Lotion
- Sunsense Sports® SPF 50+ Gel Cost:

£12.50 per pack (250ml)
Anthelios XL® SPF 50+ Melt-in Cream:
£15.00 per pack (50ml)
Likely to use: 50-75 units per year (across both hospital sites) Included in the NWL Joint Formulary
Outcome: Approved for addition to the formulary

- **Beclometasone 5mg MR Tablets (Clipper®)**

Requested by: Gastroenterology
Indication: Management of mild/moderate flares of UC
Proposal: Add to the formulary Recommended for use in BSG and ECCO IBD guidelines for mild to moderate flares of UC
Included in the NWL Joint Formulary Cost:£56.56 + VAT for 1 month
course Usage: 24 courses per year Included in the NWL Joint Formulary
Outcome: Approved for addition to the formulary

- **Fidaxomicin 40mg/ml Suspension**

Requested by: Microbiology
Indication: Management of Clostridium Difficile Infection
Proposal: Add to the formulary to support administration where there is a difficulty in the swallowing of solid oral dosage forms Cost:
Fidaxomicin 200mg Tablets
£1,620 (inc VAT) x pack of 20 units 200mg = £81 (incl VAT)
Fidaxomicin 40ml/ml Liquid
£1,620 (inc VAT) x pack of 110ml 200mg = £73 (incl VAT)
Usage: 4 packs per year
Included in the NWL Joint Formulary
Outcome: Approved for addition to the formulary

- **Luforbec 100/6 and 200/6 micrograms per actuation pressurised inhalation solution (Beclometasone 100/200 micrograms & formoterol 6 micrograms/dose) MDI**

Requested by: Respiratory Indication: Management of Asthma
Proposal: Add to the formulary as an alternative to Fostair® Luforbec® is a generic form of Fostair®. Fostair® is one of the most commonly prescribed inhalers in the Trust used in the management of patients with Asthma. Luforbec® is a like-for-like equivalent to Fostair® and costs considerably less.
Cost:
Fostair® 200/6 pMDI: £29.32 /30 days Luforbec® 200/6 pMDI: £13.98 /30 days
Usage: Trust will switch to using Luforbec pMDI ® (or Bibecfo® - Approved by TMG in June 2024) in place of Fostair pMDI® so usage is anticipated to be the same as that of Fostair® currently estimated at 3000 inhalers/annum
Included in the NWL Joint Formulary
Outcome: Approved for addition to the formulary

Approved at NWL ICB Joint Formulary Committee

- **Insulin Lispro (Lyunjev®) 100unit and 200unit/ml Insulin in Pre- filled (Kwikpen) Pen, Vial and Cartridge**

Indication: Management of Diabetes
Insulin Lispro (Lyumjev®) is recommended for the treatment of Diabetes Mellitus in adults who are suitable for Humalog® and their diabetes cannot be adequately managed with alternative formulary choices and at least one of the following applies:

- Where the prescriber believes a faster onset of action would be beneficial to the patient

- Where a patient requires 'tight' control of blood sugar levels
- Where a patient has rapid post-meal increase in blood sugar levels To replaces Insulin Aspart (Fiasp®) on the formulary.

Outcome: Approved for addition to the formulary

Removals

- **Anthelios XL® SPF 50+ Melt-in Cream**
- **Sunsense Ultra® SPF 50+ Lotion**
- **Sunsense Sports® SPF 50+ Gel**

Replaced by Anthelios® SPF 50+ Sunscreen
Outcome: Approved for removal from the formulary

- **Aspart (Fiasp®) Insulin**

Replaced by Insulin Lispro (Lyunjev®)
Outcome: Approved for removal from the formulary

NICE Approved drug applications

TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (08/05/2024)
Proposal: Add to the formulary in line with NICE TA970 Approved by Chair's action on 05/08/2024
For noting only
Outcome: Approval noted

- **TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (15/05/2024)**

Proposal: Add to the formulary in line with NICE TA974 Approved by Chair's action on 05/08/2024
For noting only
Outcome: Approval noted

- **TA979 - Ivosidenib with axacitidine for untreated acute myeloid leukaemia with and IDHR132 mutation (05/06/2024** Proposal: Add to the formulary in line with NICE TA979
Outcome: Approved

- **TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (10/07/2024)**

Proposal: Add to the formulary in line with NICE TA986
Outcome: Approve

Pharmacoeconomic Board requests

- **Adalimumab and Vedolizumab for Paediatric with UC**

Approved by Pharmacoeconomic Board on 10/05/2024 - For noting
Outcome: Approval noted

- **Mepolizumab for with idiopathic hypereosinophilic syndrome**

Approved by Pharmacoeconomic Board on 10/05/2024 - For noting
Outcome: Approval noted

4.2 Trust Medicines Policy

- **TMP: Section 15 - Clinical Trials**

Routine review and update
  - Updated HRA to include Wales
  - Updated Ethics approval to joint HRA/Ethics submissions as now part of the same submission/approval process.

Outcome: Approved

- **TMP: Section 6 - Controlled Drugs**

Ordering of Controlled Drugs reviewed in light of electronic CD ordering and section added relating to downtime.

Outcome: Approved

- **TMP: Section 8 - Administration of Medicines**

Updated in light mobilisation of CP House Vaccination Centre being under CWFT governance from July 2024:

- Pharmacist added as a staff group who can administer medicines within the Trust.
- Section added relating to action to take if an ADR occurs after administration at an off-site location

Approved via Chair's Action on 01/07/24 - For noting

Outcome: Approval noted

- **TMP: Section 17 - Injectable Medicines Policy**

Updated in light mobilisation of CP House vaccination service being under CWFT governance from July 2024

- Pharmacist added as a staff group who can administer injectable medicines within the Trust.
- Competencies added for pharmacists and pharmacy technicians who are involved in the preparation and administration of injectable medicines.

Approved via Chair's Action on 01/07/2 - For noting

Outcome: Approval noted

- **Trust Adult IV Administration Guide - Updates**

Following a discussion with the Gastroenterology Pharmacist, Practice Development Nurse and Trust IV Taskforce Chair it has been agreed for Infliximab and Ustekinumab to be updated from being administered in the following clinical areas:

- Infliximab: AEC, AAU GDC, RJ, PACC, EH and Jupiter
- Ustekinumab: AEC, AAU, GDC and RJ

to being permitted to being administered in ALL clinical areas.

Outcome: Approved

4.3 Medicines Optimisation

- **Trust Covid-19 Vaccine Handling and Management Policy**

Reviewed and updated guideline.

- Update to list of relevant Covid-19 vaccine SOPs
- Updated for the brand of Covid-19 vaccines currently procured and administered within the Trust
- Updated in light of mobilisation of CP House Vaccination Centre to being under CWFT governance from July 2024

Approved via Chair's action on 03/07/2024

Outcome: Approved

4.4 NICE TAs and HSTs

21 TA appraisals published since previous TMG meeting

TA976 - Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (29/05/2024) Formulary status / Action
Nil - Terminated Appraisal

TA977 - Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (29/05/2024)
Formulary status / Action
Included on the formulary for another indication Action: Nil as condition not treated at CWFT.

TA978 - Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (29/05/2024)
Formulary status / Action Nil - Terminated Appraisal

TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (05/06/2024)
Formulary status / Action
Azacitidine included on the formulary for another indication but Ivosidenib not included on the formulary. Application form included in

Section 4.1

TA980 - Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) (05/06/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease (12/06/2024)
Formulary status / Action
Not included on the formulary
Action: Nil as treatment not initiated at CWFT.

TA982 - Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (13/06/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA983 - Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2- positive gastric or gastro-oesophageal junction adenocarcinoma (12/06/2024)
Formulary status / Action Nil - Not recommended

TA984 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (19/06/2024)
Formulary status / Action
Not included on the formulary
Action: Nil as condition not treated at CWFT.

TA985 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (03/07/2024)
Formulary status / Action Nil - Radiotherapy

TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (10/07/2024)
Formulary status/Action
Not included on the formulary Application form included in Section 4.1

TA987 - Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (10/07/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA988 - Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (24/07/2024)
Formulary status/Action
Not included on the formulary
Action: Nil as condition not treated at CWFT.

TA989 - Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (24/07/2024) Recommendation
Formulary status/Action
Not included on the formulary
Action: Nil as condition not treated at CWFT.

TA990 - Tenecteplase for treating acute ischaemic stroke (24/07/2024)
Formulary status / Action
Included on the formulary for another indication Action: Nil as condition not treated at CWFT

TA991 - Abaloparatide for treating osteoporosis after menopause (07/08/2024)
Formulary status/Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Rheumatology Department.

TA992 - Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (29/07/2024)
Formulary status / Action
Nil - Not recommended

TA993 - Burosumab for treating X-linked hypophosphataemia in adults (07/08/2024)
Formulary status/Action
Not included on the formulary
Action: Nil as condition not treated at CWFT

TA994 - Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (08/08/2024)
Formulary status / Action
Nil - Terminated Appraisal

TA995 - Relugolix for treating hormone-sensitive prostate cancer (14/08/2024)
Formulary status/Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Oncology Department.

TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids (14/08/2024)
Formulary status/Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Gynaecology Department

b) NICE Highly Specialised Technology Appraisals published since previous TMG meeting

1 HST appraisal published since previous TMG meeting

HST31 - Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (22/05/2024)
Formulary status / Action
Included on the formulary for another indication
Action: Nil as CWFT is not commissioned.

c) NICE TA Summary for 2023/24
The Medicines Group noted **84** NICE Technology Appraisals (TA) in 2023-24.

Local clinical guidelines should reflect nationally agreed guidelines such as NICE guidance. Where a NICE guidance advocates the use of a medicine, formulary applications are requested to reflect this.

Of the 84 NICE TAs noted in 2023-24, the following actions resulted:

- 16 TAs (19%) - Terminated appraisal
- 13 TAs (16%) - Condition is not treated at the Trust
- 10 TAs (12%) - Therapy was not recommended
- 7 TAs (8%) - Trust is not a site commissioned by NICE for that particular TA
- 1 TA (1%) - Medical device
- 37 TAs (44%) - Trust Medicines Formulary was updated to indicate that the drug is used in line with the TA.

d) NICE HST Summary for 2023/24
The Medicines Group noted 7 medicines related NICE Highly Specialised Technologies (HST) in 2023-24.

All 7 NICE HSTs that were noted in 2023-24 required no further action as the therapy was not applicable to the Trust is not a site commissioned by NICE for that particular HST

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q4 2023/24**

Quarterly Controlled Drug Summary Report for Q4 2023/24
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q4 2023/24**

Quarterly CD Accountable Officer Report for Q4 2023/24
Outcome: Noted

- **Trust Medicines Group Report for Patient Safety - July 2024**

Trust Medicines Group report to Trust Patient Safety Group - July 2024
Outcome: Noted

- **Medication Safety Bulletin: Anti-Retroviral Therapy**

Medication Safety Bulletin relating to Anti-Retroviral Therapy
Outcome: Noted

- **Medication Safety Bulletin: Cerner Prescribing**

Medication Safety Bulletin relating to Cerner Prescribing
Outcome: Noted

- **Medication Safety Bulletin: Improving Opioid Safety**

Medication Safety Bulletin relating to Improving Opioid Safety
Outcome: Noted

- **MHRA Drug Safety Update - May 2024**

MHRA update for May 2024
Outcome: Noted

- **MHRA Drug Safety Update - June 2024**

MHRA update for June 2024
Outcome: Noted

- **MHRA Drug Safety Update - July 2024**

MHRA update for July 2024
Outcome: Noted

- **MHRA Drug Safety Update - August 2024**

MHRA update for August 2024
Outcome: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group meeting minutes - February 2024**

Minutes from Medication Safety Group Meeting held February 2024
Outcome: Noted

- **Medication Safety Group meeting minutes - April 2024**

Minutes from Medication Safety Group Meeting held April 2024
Outcome: Noted

- **Medication Safety Group meeting minutes - July 2024**

Minutes from Medication Safety Group Meeting held July 2024
Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting minutes - July 2024**

Minutes from for HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting held in July 2024
Outcome: Noted

5. Any other business
Nil

6. Date of next meeting
Next meeting
Date: 11th November 2024
Time: 8am-9am
Location: via Teams